|
Specific Patient Populations AMARYL (glimepiride tablets) is not recommended for use in pregnancy, nursing mothers, or children. In elderly, debilitated, or malnourished patients, or in patients with renal or hepatic insufficiency, the initial dosing, dose increments, and maintenance dosage should be conservative to avoid hypoglycemic reactions (See CLINICAL PHARMACOLOGY, Special Populations and PRECAUTIONS, General). Text Continues Below
Patients Receiving Other Oral Hypoglycemic Agents As with other sulfonylurea hypoglycemic agents, no transition period is necessary when transferring patients to AMARYL. Patients should be observed carefully (1-2 weeks) for hypoglycemia when being transferred from longer half-life sulfonylureas (e.g., chlorpropamide) to AMARYL due to potential overlapping of drug effect. HOW SUPPLIED AMARYL tablets are available in the following strengths and package sizes: 1 mg (pink, flat-faced, oblong with notched sides at double bisect, either imprinted with "AMA RYL" on one side, or imprinted with "AMA RYL" on one side and the Hoechst logo on both sides of the bisect on the other side)Bottles of 100 (NDC 0039-0221-10) 2 mg (green, flat-faced, oblong with notched sides at double bisect, either imprinted with "AMA RYL" on one side, or imprinted with "AMA RYL" on one side and the Hoechst logo on both sides of the bisect on the other side)Bottles of 100 (NDC 0039-0222-10)
Unit Dose Cartons (100) (NDC 0039-0222-11) 4 mg (blue, flat-faced, oblong with notched sides at double bisect, either imprinted with "AMA RYL" on one side, or imprinted with "AMA RYL" on one side and the Hoechst logo on both sides of the bisect on the other side)Bottles of 100 (NDC 0039-0223-10)
Unit Dose Cartons (100) (NDC 0039-0223-11) Store between 59 and 86° F (15 and 30° C). Dispense in well-closed containers with safety closures. Page: << Prev | 1 | 2 | 3 | 4 | 5 | Next >>
|
.gif)
